Mwyngil Therapeutics, a new biotech startup, is tackling obesity with a unique approach that doesn't involve the popular GLP-1 target. CEO Luba Greenwood explains why the company is taking a different path in the multibillion-dollar weight loss market.
Medicare's new 'Bridge' program aims to make GLP-1 weight loss medications more affordable, but its complex eligibility criteria and administrative burdens may limit access for patients. The program, which offers discounted access to medications like Wegovy and Zepbound, requires extensive documentation and prior authorizations, which can delay treatment and increase staff workload.
Millions of Americans have lost insurance coverage for weight loss drugs like Zepbound and Wegovy, forcing them to navigate a complex appeals process or seek alternative treatments. Patients and doctors are speaking out about the challenges of accessing these medications, which have been shown to be effective in treating obesity and related conditions.